EI
STSA

EAM Investors’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

EAM Investors’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-149,029
Closed -$894K – 370
2022
Q3 		$894K Buy
+149,029
New +$845K 0.19% 230

Other funds holding STSA

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

EAM Investors's STSA Position: Q4 2022 in Review

EAM Investors sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2022, closing a stake of 149,029 shares — an estimated $894K sold.

EAM Investors first reported a position in STSA in Q3 2022 and held it in 1 quarter. The position peaked at $894K in Q3 2022. 33 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

  • EAM Investors reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • EAM Investors sold 149,029 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $894K.
  • EAM Investors first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • EAM Investors's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $894K in Q3 2022.
  • 33 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on EAM Investors's 13F filing for Q4 2022, filed 14 Feb 2023.